Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma

Oncogene

Volumn 31, Issue 16, 2012, Pages 2007-2016

  Lu, C ^a   Zhu, X ^a   Willingham, M C ^b   Cheng, S Y ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

animal model; follicular thyroid carcinoma; protein kinase B AKT; PTEN; thyroid hormone

Indexed keywords

BETA CATENIN; BROXURIDINE; CASPASE 3; CYCLIN D2; GELATINASE A; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; THYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INVASION; CARCINOGENESIS; CELL PROLIFERATION; METASTASIS; MOLECULAR GENETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

ANIMALS; ANTITHYROID AGENTS; CELL PROLIFERATION; CYCLIN D2; DISEASE MODELS, ANIMAL; MICE; PROPYLTHIOURACIL; SIGNAL TRANSDUCTION; THYROID HORMONE RECEPTORS BETA; THYROID HORMONES; THYROID NEOPLASMS; THYROTROPIN;

ANIMALIA; MUS;

EID: 84859893531     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.390     Document Type: Article

References (50)

1. Abbosh PH, Nephew KP. (2005). Multiple signaling pathways converge on beta-catenin in thyroid cancer. Thyroid 15: 551-561. (Pubitemid 40993728)
2. Antico-Arciuch VG, Dima M, Liao XH, Refetoff S, Di Cristofano A. (2010). Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. Oncogene 29: 5678-5686.
3. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S et al. (2005). Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146: 2864-2871. (Pubitemid 41002793)
4. Boelaert K, McCabe CJ, Tannahill LA, Gittoes NJ, Holder RL, Watkinson JC et al. (2003). Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab 88: 2341-2347. (Pubitemid 36549916)
5. Cao X, Kambe F, Moeller LC, Refetoff S, Seo H. (2005). Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. Mol Endocrinol 19: 102-112. (Pubitemid 40065962)
6. Castellone MD, De Falco V, Rao DM, Bellelli R, Muthu M, Basolo F et al. (2009). The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res 69: 1867-1876.
7. Cheng SY, Leonard JL, Davis PJ. (2010). Molecular aspects of thyroid hormone actions. Endocr Rev 31: 139-170.
8. Cole AM, Myant K, Reed KR, Ridgway RA, Athineos D, Van den Brink GR et al. (2010). Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. Cancer Res 70: 8149-8158.
9. Davies L, Welch HG. (2006). Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167.
10. Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, Cao HJ et al. (2004). Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 94: 1500-1506. (Pubitemid 38780323)
11. Davis PJ, Davis FB, Lin H-Y, Mousa SA, Zhou M, Luidens MK. (2009). Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metabol 297: E1238-E1246.
12. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H et al. (2007). Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 282: 11221-11229. (Pubitemid 47100795)
13. Furumoto H, Ying H, Chandramouli GV, Zhao L, Walker RL, Meltzer PS et al. (2005). An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol 25: 124-135. (Pubitemid 40039805)
14. Furuya F, Hanover JA, Cheng SY. (2006). Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc Natl Acad Sci USA 103: 1780-1785. (Pubitemid 43228770)
15. Furuya F, Lu C, Willingham MC, Cheng SY. (2007). Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 28: 2451-2458. (Pubitemid 350238946)
16. Glinskii AB, Glinsky GV, Lin HY, Tang HY, Sun M, Davis FB et al. (2009). Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 8: 3554-3562.
17. Guigon CJ, Cheng SY. (2009). Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis. Mol Cell Endocrinol 308: 63-69.
18. Guigon CJ, Kim DW, Zhu X, Zhao L, Cheng SY. (2010). Tumor suppressor action of liganded thyroid hormone receptor beta by direct repression of beta-catenin gene expression. Endocrinology 151: 5528-5536.
19. Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY. (2008). Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol Cell Biol 28: 4598-4608. (Pubitemid 351977757)
20. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S et al. (2007). Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13: 1161-1170. (Pubitemid 46424056)
21. Kaneshige M, Kaneshige K, Zhu X, Dace A, Garrett L, Carter TA et al. (2000). Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci USA 97: 13209-13214.
22. Keniry M, Parsons R. (2008). The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27: 5477-5485.
23. Kessenbrock K, Plaks V, Werb Z. (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67.
24. Kim CS, Ying H, Willingham MC, Cheng SY. (2007). The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis 28: 932-939. (Pubitemid 47072175)
25. Liang J, Slingerland JM. (2003). Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2: 339-345.
26. Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA et al. (2009). L-Thyroxine vs 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 296: C980-C991.
27. Lin HY, Tang HY, Shih A, Keating T, Cao G, Davis PJ et al. (2007). Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 72: 180-187. (Pubitemid 46273502)
28. Lu C, Cheng SY. (2011). Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis. Steroids 76: 885-891.
29. Lu C, Mishra A, Zhu YJ, Meltzer P, Cheng SY. (2011). Genomic profiling of genes contributing to metastasis in a mouse model of thyroid follicular carcinoma. Am J Cancer Res 1: 1-13.
30. Lu C, Zhao L, Ying H, Willingham MC, Cheng SY. (2010). Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Endocrinology 151: 1929-1939.
31. Mousa SA, Davis FB, Mohamed S, Davis PJ, Feng X. (2006). Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Int Angiol 25: 407-413. (Pubitemid 46351000)
32. Nikiforov YE. (2004). Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 15: 319-327.
33. Nikiforova MN, Nikiforov YE. (2009). Molecular diagnostics and predictors in thyroid cancer. Thyroid 19: 1351-1361.
34. Ono S, Schwartz ID, Mueller OT, Root AW, Usala SJ, Bercu BB. (1991). Homozygosity for a dominant negative thyroid hormone receptor gene responsible for generalized resistance to thyroid hormone. J Clin Endocrinol Metab 73: 990-994. (Pubitemid 21901136)
35. Parrilla R, Mixson AJ, McPherson JA, McClaskey JH, Weintraub BD. (1991). Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two 'hot spot' regions of the ligand binding domain. J Clin Invest 88: 2123-2130.
36. Puxeddu E, Romagnoli S, Dottorini ME. (2011). Targeted therapies for advanced thyroid cancer. Curr Opin Oncol 23: 13-21.
37. Rego-Iraeta A, Perez-Mendez LF, Mantinan B, Garcia-Mayor RV. (2009). Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid 19: 333-340.
38. Rowlands TM, Pechenkina IV, Hatsell S, Cowin P. (2004). Betacatenin and cyclin D1: connecting development to breast cancer. Cell Cycle 3: 145-148. (Pubitemid 40268685)
39. Saji M, Ringel MD. (2010). The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 321: 20-28.
40. Sassolas G, Hafdi-Nejjari Z, Remontet L, Bossard N, Belot A, Berger-Dutrieux N et al. (2009). Thyroid cancer: is the incidence rise abating? Eur J Endocrinol 160: 71-79.
41. Sipos JA, Mazzaferri EL. (2010). Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 22: 395-404.
42. Sonderegger S, Haslinger P, Sabri A, Leisser C, Otten JV, Fiala C et al. (2010). Wingless (Wnt)-3A induces trophoblast migration and matrix metalloproteinase-2 secretion through canonical Wnt signaling and protein kinase B/AKT activation. Endocrinology 151: 211-220.
43. Suzuki H, Willingham MC, Cheng SY. (2002). Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 12: 963-969. (Pubitemid 35404130)
44. Verga Falzacappa C, Petrucci E, Patriarca V, Michienzi S, Stigliano A, Brunetti E et al. (2007). Thyroid hormone receptor TRbeta1 mediates Akt activation by T3 in pancreatic beta cells. J Mol Endocrinol 38: 221-233. (Pubitemid 46351605)
45. Weinberger PM, Adam BL, Gourin CG, Moretz 3rd WH, Bollag RJ, Wang BY et al. (2007). Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg 133: 503-510. (Pubitemid 46799789)
46. Xing M. (2010). Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 20: 697-706.
47. Yalcin M, Bharali DJ, Dyskin E, Dier E, Lansing L, Mousa SS et al. (2010). Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid 20: 281-286.
48. Ying H, Furuya F, Zhao L, Araki O, West BL, Hanover JA et al. (2006). Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J Clin Invest 116: 2972-2984. (Pubitemid 44684482)
49. Ying H, Suzuki H, Zhao L, Willingham MC, Meltzer P, Cheng SY. (2003). Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis. Cancer Res 63: 5274-5280. (Pubitemid 37139841)
50. Ying H, Willingham MC, Cheng SY. (2008). The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer. Oncogene 27: 823-830. (Pubitemid 351186318)